Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / YWHAQ

YWHAQ

Basics

Aliases:
This biomarker is also known as:
  • 14-3-3 protein T-cell,
  • 14-3-3 theta,
  • 14-3-3 protein theta,
  • 14-3-3 protein tau,
  • protein tau,
  • 1C5,
  • Protein HS1,
  • tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, theta polypeptide,

View in BioMuta

Description…

14-3-3 theta belongs to the 14-3-3 family of proteins which mediate signal transduction by binding to phosphoserine-containing proteins. This highly conserved protein family is found in both plants and mammals, and this protein is 99% identical to the mouse and rat orthologs. The 14-3-3 proteins have a wide range of ligands, are involved in a variety of biological pathways, and are known to be overexpressed in some human lung cancers, suggesting that they may play a role in tumorigenesis. 14-3-3 theta is an adapter protein implicated in the regulation of a large spectrum of both general and specialized signaling pathway. It binds to a large number of partners, usually by recognition of a phosphoserine or phosphothreonine motif. Binding generally results in the modulation of the activity of the binding partner. 14-3-3 theta antigens have been found to be targets of autoantibodies in subjects newly diagnosed with lung cancer.

Attributes

QA State: Accepted
Type: Protein
Short Name:
HGNC Name: YWHAQ

Organs

The following organs have data associated with this biomarker…

Lung

Attributes

Phase: Three
QA State: Under Review

Overview

14-3-3 theta, previously found to be the target of autoantibodies in newly diagnosed subjects with lung cancer, is also associated with autoantibodies in sera collected at the pre-symptomatic stage. These findings suggest potential utility of an approach to diagnosis of lung cancer before onset of symptoms that includes screening for autoantibodies to defined antigens, including 14-3-3 theta.

Performance Comment

The findings of this study suggest potential utility of an approach to diagnosis of lung cancer before onset of symptoms that includes screening for autoantibodies to defined antigens. Investigation of 14-3-3 theta is ongoing.

Supporting Study Data

The following studies/protocols provide evidence supporting YWHAQ indications for the Lung…

Validation of Protein Markers for Lung Cancer Using CARET Sera and Proteomics Techniques

1.1 To validate the finding from pilot studies with CARET sera of autoantibodies to annexins I and II and PGP9.5 as potential biomarkers for lung cancers before the clinical diagnosis, evaluating sensitivity and specificity by time before diagnosis, treatment arm, gender, histologic type, and smoking status. 1.2 To determine whether a pattern of occurrence of autoantibodies in lung cancer sera may be diagnostic of lung cancer that is not dependent on the occurrence of any particular autoantibody. 1.3 To compare the findings for individual biomarker candidates and combinations of biomarker candidates in participants who were current smokers versus former smokers.

View more about this study
Biomarker Characteristics Summary
Notes Sensitivity Specificity Prevalence NPV PPV Specific Assay Type
Individual sera collected from 85 subjects within a year prior to a diagnosis of lung cancer and 85 matched controls from the CARET cohort were used in this analysis. Sam Hanash laboratory. 51.0 82.0 N/A N/A N/A
Decision Rule

PMID: 18794547

Additional Study-Specific Protocols
Study-Specific Publications
Study-Specific Resources

Organ-Specific Protocols

No organ-specific protocols defined.

Organ-Specific Publications

No organ-specific publications defined.

Organ-Specific Resources

No organ-specific resources defined.

New Funding Opportunity: Biomarker Development Laboratories for the Early Detection Network: Applications Due May 23

Update: Pre-application webinar information now available.

The National Cancer Institute's Division of Cancer Prevention has released a new funding opportunity to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers.

The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this funding opportunity) should be focused on one or more of the following cancers: breast, prostate and other genitourinary organs, or lung. In addition, cancers with rapidly rising incidence rates, e.g., endometrial, hepatocellular, kidney, thyroid, oropharyngeal cancers, and/or cancers with unique etiology, e.g., mesothelioma, will be considered.

The newly funded units of the Early Detection Research Network will be announced later in April. Successful applicants have already been notified. Those researchers who were not successful during the last round of applications are encouraged to apply to this opportunity.